{"id":54872,"date":"2026-01-20T20:18:41","date_gmt":"2026-01-20T12:18:41","guid":{"rendered":"https:\/\/flcube.com\/?p=54872"},"modified":"2026-01-20T20:18:42","modified_gmt":"2026-01-20T12:18:42","slug":"aideas-adc205-hiv-combo-gets-nmpa-nod-for-clinical-trials-targeting-2-8b-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54872","title":{"rendered":"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market"},"content":{"rendered":"\n<p><strong>Jiangsu Aidea Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688488:SHA\">SHA: 688488<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved clinical trials for <strong>ADC205<\/strong>, a <strong>fixed\u2011dose combination<\/strong> of <strong>dolutegravir, lamivudine, and tenofovir<\/strong> for <strong>HIV\u20111 infection<\/strong>, marking the company\u2019s entry into the <strong>global $2.8\u202fbillion HIV antiretroviral market<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Aidea Pharmaceutical Co., Ltd (688488.SH)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>ADC205 (dolutegravir\/lamivudine\/tenofovir FDC)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>IND (Investigational New Drug)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td>**Indication<\/td><td>Complete regimen for HIV\u20111 infection<\/td><\/tr><tr><td>**Population<\/td><td>Adults and pediatrics \u226535\u202fkg<\/td><\/tr><tr><td>**Approval Date<\/td><td>16\u202fJan\u202f2026<\/td><\/tr><tr><td>**Formulation<\/td><td>Fixed\u2011dose combination tablet<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-composition-amp-mechanism\">Drug Composition &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Dose<\/th><th>Mechanism<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Dolutegravir sodium<\/strong><\/td><td>50\u202fmg<\/td><td>Integrase strand transfer inhibitor (INSTI)<\/td><td>Marketed globally<\/td><\/tr><tr><td><strong>Lamivudine<\/strong><\/td><td>300\u202fmg<\/td><td>Nucleoside reverse transcriptase inhibitor (NRTI)<\/td><td>Marketed globally<\/td><\/tr><tr><td><strong>Tenofovir DF<\/strong><\/td><td>300\u202fmg<\/td><td>Nucleotide reverse transcriptase inhibitor (NtRTI)<\/td><td>Marketed globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Synergistic Benefits:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simplified regimen:<\/strong> Single tablet once daily vs. 2\u20113 separate pills<\/li>\n\n\n\n<li><strong>Reduced pill burden:<\/strong> Improves adherence in chronic HIV management<\/li>\n\n\n\n<li><strong>Resistance mitigation:<\/strong> Triple mechanism reduces risk of viral breakthrough<\/li>\n\n\n\n<li><strong>Cost advantage:<\/strong> Generic pricing strategy targets <strong>Tier\u20112\/3 hospitals<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>HIV\u20111 Patients on ART<\/strong><\/td><td>1.25\u202fmillion<\/td><td>28.5\u202fmillion<\/td><\/tr><tr><td><strong>Fixed\u2011Dose Combination Penetration<\/strong><\/td><td>65\u202f%<\/td><td>78\u202f%<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>\u00a518\u202fbillion<\/td><td>$2.8\u202fbillion<\/td><\/tr><tr><td><strong>Generics Market Share<\/strong><\/td><td>45\u202f%<\/td><td>32\u202f%<\/td><\/tr><tr><td><strong>ADC205 Peak Revenue<\/strong><\/td><td>\u00a5920\u202fmillion<\/td><td>$85\u202fmillion<\/td><\/tr><tr><td><strong>Launch Timeline<\/strong><\/td><td>2028 (China)<\/td><td>2030 (ex\u2011China via partnership)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biktarvy<\/strong> (Gilead) \u2013 Market leader, patented until 2032<\/li>\n\n\n\n<li><strong>Dovato<\/strong> (ViiV) \u2013 Dual therapy, limited to select patients<\/li>\n\n\n\n<li><strong>Generic equivalents<\/strong> \u2013 <strong>Dolutegravir\/lamivudine\/tenofovir<\/strong> (Mylan, Aurobindo) \u2013 ADC205\u2019s direct competitors<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> ADC205\u2019s <strong>China\u2011specific formulation<\/strong> and <strong>local manufacturing<\/strong> enable <strong>30\u201140% cost savings<\/strong> vs. imports<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Aidea\u2019s <strong>Jiangsu facility<\/strong> (capacity 5\u202fbillion tablets\/year) will produce ADC205; <strong>WHO Pre\u2011qualification<\/strong> targeted by 2027 for export markets<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> <strong>Phase\u202fIII bridging study<\/strong> vs. Biktarvy planned for <strong>Q2\u202f2026<\/strong>; <strong>bioequivalence data<\/strong> to leverage existing dolutegravir safety database<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> Existing <strong>3,500\u2011hospital network<\/strong> for hepatitis generics can be repurposed for HIV; <strong>NRDL negotiation<\/strong> planned for 2028<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Seeking <strong>ex\u2011China licensing<\/strong> with <strong>Mylan\/Viatris<\/strong> for <strong>low\u2011middle income markets<\/strong> upon China approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial forecasts for ADC205. Actual results may differ due to competitive dynamics, pricing pressures, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688488_20260120_YMK6-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688488_20260120_YMK6.\"><\/object><a id=\"wp-block-file--media-d117266f-2970-429a-aa77-8bdf0419906b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688488_20260120_YMK6-1.pdf\">688488_20260120_YMK6<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688488_20260120_YMK6-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d117266f-2970-429a-aa77-8bdf0419906b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[619,62,988],"class_list":["post-54872","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-aidea-pharmaceutical","tag-clinical-trial-approval-initiation","tag-sha-688488"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for ADC205, a fixed\u2011dose combination of dolutegravir, lamivudine, and tenofovir for HIV\u20111 infection, marking the company\u2019s entry into the global $2.8\u202fbillion HIV antiretroviral market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54872\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for ADC205, a fixed\u2011dose combination of dolutegravir, lamivudine, and tenofovir for HIV\u20111 infection, marking the company\u2019s entry into the global $2.8\u202fbillion HIV antiretroviral market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54872\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T12:18:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T12:18:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54872#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54872\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market\",\"datePublished\":\"2026-01-20T12:18:41+00:00\",\"dateModified\":\"2026-01-20T12:18:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54872\"},\"wordCount\":371,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aidea Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688488\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54872#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54872\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54872\",\"name\":\"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-20T12:18:41+00:00\",\"dateModified\":\"2026-01-20T12:18:42+00:00\",\"description\":\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for ADC205, a fixed\u2011dose combination of dolutegravir, lamivudine, and tenofovir for HIV\u20111 infection, marking the company\u2019s entry into the global $2.8\u202fbillion HIV antiretroviral market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54872#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54872\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54872#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for ADC205, a fixed\u2011dose combination of dolutegravir, lamivudine, and tenofovir for HIV\u20111 infection, marking the company\u2019s entry into the global $2.8\u202fbillion HIV antiretroviral market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54872","og_locale":"en_US","og_type":"article","og_title":"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market","og_description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for ADC205, a fixed\u2011dose combination of dolutegravir, lamivudine, and tenofovir for HIV\u20111 infection, marking the company\u2019s entry into the global $2.8\u202fbillion HIV antiretroviral market.","og_url":"https:\/\/flcube.com\/?p=54872","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-20T12:18:41+00:00","article_modified_time":"2026-01-20T12:18:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54872#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54872"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market","datePublished":"2026-01-20T12:18:41+00:00","dateModified":"2026-01-20T12:18:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54872"},"wordCount":371,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aidea Pharmaceutical","Clinical trial approval \/ initiation","SHA: 688488"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54872#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54872","url":"https:\/\/flcube.com\/?p=54872","name":"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-20T12:18:41+00:00","dateModified":"2026-01-20T12:18:42+00:00","description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for ADC205, a fixed\u2011dose combination of dolutegravir, lamivudine, and tenofovir for HIV\u20111 infection, marking the company\u2019s entry into the global $2.8\u202fbillion HIV antiretroviral market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54872#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54872"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54872#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aidea\u2019s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54872"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54872\/revisions"}],"predecessor-version":[{"id":54877,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54872\/revisions\/54877"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}